Paris (dpa -AfX) – The pharmaceutical company Sanofi looks back on an unexpected sales year 2024. With an increase in revenues by 8.6 (currency -adjusted plus 11.3) percent to a good 41 billion euros, the French beat themselves better than expected. In addition, a sprint in the final quarter helped, in which sales in the pharmaceutical division rose suddenly, as the group announced in Paris on Thursday. Above all, Sanofi benefited from his proven treasurer Dupixent and the respiratory drug Beyfortus. The operational profit, which was adjusted for special effects, rose by 1.5 percent to a good 11.3 billion euros. The bottom line was that the adjusted profit decreased slightly to 8.9 billion euros due to higher costs for research and development. This made Sanofi expectations on the earnings.
In the meantime, the group announced a five billion euro share buyback for the new year. In addition, Sanofi is doing better profit development for 2025 than in the past year: The adjusted winner, which was highly regarded by analysts, should attract a profit per share at constant exchange rates and apart from buyback in the lower double -digit percentage range. In 2024, the value had climbed by a good 4 percent to 7.12 euros away from the exchange rates, but decreased by almost two percent nominal. Sanofi wants to increase its currency-adjusted sales in the current twelve-month period in the medium to high single-digit percentage range ./tav/tih
Selected leverage products on Sanofi
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on Sanofi
The lever must be between 2 and 20
Advertising